Clinical Trial to Evaluate the Safety, Pharmacokinetic Characteristics of DW5124 and DW5124-R, and the Effect of Food on DW5124 in Healthy Adult Volunteers
NCT ID: NCT07319559
Last Updated: 2026-01-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
55 participants
INTERVENTIONAL
2025-05-08
2025-06-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Trial for Evaluation of Adequate Dose and Safety of DW-3102 in Hypercholesterolemia Patients
NCT02368613
A Observational Study to Evaluate Lipid-lowering Drug Its Effect on Parameters in Dyslipidemia of Type 2 Diabetes.
NCT02382159
Choline Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia
NCT05365425
A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood
NCT05979428
A Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of DWC202206 and DWC202207 in Patients With Concomitant Hypertension and Hyperlipidemia
NCT05643508
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sequence A
cross-over
DW5124
DW5124 on fasted or fed condition
DW5124-R
DW5124-R on fasted or fed condition
Sequence B
cross-over
DW5124
DW5124 on fasted or fed condition
DW5124-R
DW5124-R on fasted or fed condition
Sequence C
cross-over
DW5124
DW5124 on fasted or fed condition
DW5124-R
DW5124-R on fasted or fed condition
Sequence D
cross-over
DW5124
DW5124 on fasted or fed condition
DW5124-R
DW5124-R on fasted or fed condition
Sequence E
cross-over
DW5124
DW5124 on fasted or fed condition
DW5124-R
DW5124-R on fasted or fed condition
Sequence F
cross-over
DW5124
DW5124 on fasted or fed condition
DW5124-R
DW5124-R on fasted or fed condition
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DW5124
DW5124 on fasted or fed condition
DW5124-R
DW5124-R on fasted or fed condition
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body weight ≥50.0 kg and BMI between 18.0 and 30.0 kg/m2
Exclusion Criteria
* In the case of women, pregnant(Urine-HCG positive) or lactating women
19 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Daewon Pharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chungbuk National University Hospital
Cheongju-si, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DW5124-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.